Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Plasma Lipidomic Signatures of Pericoronary Adipose Tissue Inflammation Link to the Severity of Coronary Artery Disease in T2DM

ABSTRACT: Glycation of apolipoprotein A-I (apoA-I) compromises its cardiovascular protection, yet its pathogenic landscape remains poorly defined. Using unbiased glycation proteomics, we profiled apoA-I glycation in HDL from 1,154 patients with type 2 diabetes mellitus with or without coronary atherosclerosis (CAS). CAS-associated glycation types, frequencies, and key sites enabled construction of an apoA-I glycation index. An engineered anti-glycation apoA-I mutant restored HDL reverse cholesterol transport and inhibited atherogenesis by preventing TR4-mediated suppression of macrophage cholesterol efflux.

ORGANISM(S): Homo Sapiens

SUBMITTER: Rong Zeng

PROVIDER: PXD073437 | iProX | Thu Jan 22 00:00:00 GMT 2026

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux

Project description:Specific mutations in Apolipoprotein A-I (ApoA-I) of high-density lipoprotein (HDL) are responsible for a late-onset systemic amyloidosis. Carriers do not exhibit increased cardiovascular disease risk despite reduced levels of ApoA-I/ HDL-cholesterol. To explain this paradox, we show that the HDL particle profile of L75P and L174S patients presents a higher relative abundance of the 8.4 nm vs 9.6 nm particles, and that serum from patients, as well as reconstituted 8.4 and 9.6 nm HDL particles (rHDL), possess increased capacity to catalyze cholesterol efflux from macrophages. Synchrotron radiation circular dichroism and hydrogen-deuterium exchange revealed that the variants in 8.4 nm rHDL have altered secondary structure composition and display a more flexible binding to lipids compared to their native counterpart. The reduced HDL-cholesterol levels of patients carrying ApoA-I amyloidogenic variants are thus balanced by higher proportion of small, dense HDL particles and better cholesterol efflux due to altered, region-specific protein structure dynamics.

2020-11-20 | PXD021266 | Pride

Human Cerebrospinal Fluid HDL-like proteome from Alzheimer Disease patients

Project description:Apolipoprotein (Apo) E4 is a key genetic risk factor for Alzheimer’s disease (AD). In the central nervous system, ApoE-containing high-density lipoprotein (HDL)-like particles transport glial cholesterol to neurons, playing a crucial role in neuronal membrane remodeling and maintenance of the myelin sheath. Despite this, the impact of HDL-like cholesterol trafficking on AD pathogenesis is not yet fully understood.The objective was to examine cholesterol transport via HDL-like particles in cerebrospinal fluid (CSF) of AD patients compared to control individuals. Additionally, we explored the ability of ApoE4-containing HDL to regulate the cholesterol efflux pathway in astrocytoma cells and facilitate cholesterol delivery to neurons.Mass spectrometry (MS) was used for a detailed analysis of the HDL-like proteome in AD patients and controls.

2025-09-08 | PXD057614 | Pride

Expression data from human coronary artery endothelial cells treated with HDL components

Project description:We quantified differential gene (mRNA) expression in human coronary artery cells treated with native HDL, reconstituted HDL, lipid-free apolipoprotein A-I, small unilamellar vesicles, or PBS control. These data were used to determine which genes are regulated by native HDL compared to components of HDL and categorize data based on shared sets of genes and distinct sets of genes regulated by each component. Each group had a n=5 and gene expression changes for each condition were compared to control PBS-treated HCAECs

2014-02-27 | E-GEOD-53201 | biostudies-arrayexpress

MicroRNA expression data from human coronary artery endothelial cells treated with HDL components

Project description:We quantified differential microRNA (miRNA) expression in human coronary artery cells treated with native HDL, reconstituted HDL, lipid-free apolipoprotein A-I, small unilamellar vesicles, or PBS control. These data were used to determine whichmiRNAs are regulated by native HDL compared to components of HDL and categorize data based on shared sets of miRNAs and distinct sets of miRNAs regulated by each component. Each group had a n=5 and gene expression changes for each condition were compared to control PBS-treat HCAECs

2014-02-27 | E-GEOD-53315 | biostudies-arrayexpress

MicroRNA expression data from human coronary artery endothelial cells treated with HDL components

2014-02-27 | GSE53315 | GEO

Expression data from human coronary artery endothelial cells treated with HDL components

2014-02-27 | GSE53201 | GEO

ApoA-I [human] (CSL112) infusion increases LCAT levels in HDL particles and promotes reverse cholesterol transport

Project description:Background: High-density lipoprotein (HDL)-cholesterol is inversely correlated with cardiovascular risk, but increasing its circulating concentration is insufficient to prevent adverse cardiovascular outcomes. Instead, the emerging paradigm is on increasing the function of HDL and its major protein constituent, apolipoprotein A-I (apoA-I) to increase reverse cholesterol transport. Objective: To investigate the effect of apoA-I [human] (CSL112) infusion on HDL protein composition, and provide further insights into the mechanism of action of CSL112 administered post-acute myocardial infarction (AMI). Methods: A mass spectrometry (MS)-based proteomic approach was used to evaluate changes in HDL protein composition in patients (n=50) from the AEGIS-I (ApoA-I Event Reducing in Ischemic Syndromes I) study who received either placebo or CSL112 post-AMI. HDL was immuno-isolated from patient plasma using anti-apoA-I antibodies. Cholesterol esterification rate (CER) was measured to determine lecithin-cholesterol acyl transferase (LCAT) activity. Cholesterol efflux capacity (CEC) and hepatocyte uptake were assessed using patient serum in ex vivo cell-based assays. Results: CSL112 induced extensive rearrangement of HDL proteins at 4 hours post-infusion. Levels of apolipoproteins A2, B, C, and E, as well as the acute phase proteins serum amyloid A1 and A4 were significantly reduced. By contrast, apoA-I, apoM, and LCAT significantly increased. Elevated apoA-I and LCAT levels on HDL were associated with an increase in CEC, plasma HDL-C levels, and CER in CSL112-treated patients. Furthermore, enhanced CEC was strongly associated with cholesterol uptake by hepatic cells (r=0.95 p<0.001). Conclusions: CSL112 altered HDL composition and increased HDL functionality by promoting multiple steps of the reverse cholesterol transport pathway. Clinical trial registration: URL: https://clinicaltrials.gov. Unique identifier: NCT02108262

2025-06-16 | PXD057196 | Pride

Differential top-down quantitation of Apo-AI

Project description:Top-down quantitative analysis of Apolipoprotein A1 from two sets of participants reveals differential proteoform expression in high or low HDL efflux capacity groups.

2018-02-09 | MSV000082051 | MassIVE

HDL suppresses the type I interferon response

Project description:Background: High density lipoprotein (HDL) protects the artery wall by removing cholesterol from lipid-laden macrophages. However, recent evidence suggests that it might also inhibit atherogenesis by combating inflammation. Methods and Results: To identify potential anti-inflammatory mechanisms, we challenged macrophages with lipopolysaccharide (LPS), an inflammatory microbial ligand for Toll-like receptor 4 (TLR4). HDL inhibited the expression of 33% (301 of 911) of the genes normally induced by LPS, microarray analysis revealed. One of its major targets was the type I interferon response pathway, a family of potent viral immunoregulators controlled by TLR4 and the TRAM/TRIF signaling pathway. Unexpectedly, HDL’s ability to inhibit gene expression was independent of cellular cholesterol stores. Moreover, it was unaffected by downregulation of two ATP-binding cassette transporters, ABCA1 and ABCG1, that promote cholesterol efflux. To examine the pathway’s potential in vivo relevance, we used mice deficient in apolipoprotein (apo) A-I, HDL’s major protein. After infection with Salmonella (a Gram-negative bacterium that expresses LPS), apoA-I–deficient mice had 6-fold higher plasma levels of interferon-beta-a key regulator of the type I interferon response than did wild-type mice. Conclusions: HDL inhibits a subset of LPS-stimulated macrophage genes that regulate the type I interferon response, and its action is independent of sterol metabolism. These findings raise the possibility that regulation of macrophage genes by HDL might link innate immunity and cardioprotection. 12 arrays, 3 experimental groups, mMncN (no treatment), mMncL (LPS treated, exposed for 4 h to serum-free medium or serum-free medium supplemented with 100 ng/mL of LPS), and mMwtL (HDL treated, Macrophages were treated for 4 h with serum-free medium or serum-free medium supplemented with 50 mg/mL of HDL, washed twice with PBS).

2010-10-01 | E-GEOD-19340 | biostudies-arrayexpress

HDL suppresses the type I interferon response

2010-10-01 | GSE19340 | GEO